RWE

Real-World Evidence Confirms IDgenetix®-Guided Medication Management Significantly Improves Response and Remission Rates in Patients with Major Depressive Disorder

Retrieved on: 
Wednesday, November 8, 2023
Other Health, Pharmaceutical, Optical, Oncology, General Health, Mental Health, Medical Devices, Neurology, Genetics, Clinical Trials, Biotechnology, Science, Other Science, Research, Health, Medical Supplies, Real-World Evidence, NEI, MDD, Congress, Medication, RWE, RCT, Bradley, Poster, Major depressive disorder, Depression, Patient, Randomized controlled trial, Grammatical mood, DDI, Medical device

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced data from a single-site, open-label study demonstrating the consistent impact of IDgenetix® on medication response and remission rates in patients with major depressive disorder (MDD).

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced data from a single-site, open-label study demonstrating the consistent impact of IDgenetix® on medication response and remission rates in patients with major depressive disorder (MDD).
  • Compared to patients in the unguided group, response rates for the IDgenetix-guided participants improved by 37% in the RCT vs. 32% in the RWE.
  • Overall, comparing the clinical outcome results from the RCT with RWE demonstrated the consistent impact of IDgenetix on patient response and remission rates.
  • This study provides evidence-based research that supports the clinical use of IDgenetix to guide medication management in patients with MDD.

Introducing Cercle - AI Bridging the Gap in Women's Healthcare

Retrieved on: 
Wednesday, November 8, 2023
Fertility, Knowledge, Woman, FDA, RWD, Roger Hawkins (drummer), Copenhagen, HIPAA, Real world evidence, Genetics, Congress, Medtech, USF, RWE, Research, University of Copenhagen Faculty of Health and Medical Sciences, IVF, Genomics, Real, Medicine, Partnership, University, Privacy, Clinic, AI, Real world data, Patient, Acceleration, Medical imaging, Medical device, Nursing, Cercle

SAN FRANCISCO, Nov. 8, 2023 /PRNewswire/ -- Cercle, an AI technology company unlocking comprehensive and secure data insights for the healthcare industry, announced its launch today. Its technology platform, the Cercle™ Biomedical Graph, is the first and only of its kind, harnessing and connecting billions of anonymized biomedical and genomics data points drawn securely from healthcare clinics and research labs around the world. When channeled through the Cercle™ Biomedical Graph, these data points become a treasure trove of insights for clinics, medical researchers, healthcare providers, patients, and the rest of the healthcare  ecosystem. These data insights can accelerate medical discoveries in the pharmaceutical and research fields, enable the acceleration of precision medicine and personalized treatments, help clinics improve the efficiency and effectiveness of  medical care, and ultimately, drive better health outcomes. The company has already partnered with two trusted healthcare institutions, Eurofins Genoma and US Fertility.

Key Points: 
  • When channeled through the Cercle™ Biomedical Graph, these data points become a treasure trove of insights for clinics, medical researchers, healthcare providers, patients, and the rest of the healthcare  ecosystem.
  • Cercle is launching first in fertility and women's healthcare, ushering in a new age of accuracy, knowledge and clarity in a historically under-researched and under-funded medical field.
  • Cercle utilizes AI technology to harmonize and transform this raw and fragmented data into accurate insights that help improve patient outcomes.
  • Cercle plans to support doctors, clinics, biotech and pharmaceutical researchers, and healthcare communities across many women's healthcare verticals and needs beyond fertility in the future.

Kythera Labs Announces $20 Million Funding to Accelerate Growth of its Wayfinder Data Technology Platform

Retrieved on: 
Tuesday, November 7, 2023
Roivant Sciences, RWD, CSO, CIBC, Health care, CCO, Arbutus Biopharma, Entrepreneurship, Research, RWE, Growth, Conference on Semantics in Healthcare and Life Sciences, Partnership, Kythira, Chief commercial officer, Databricks, Datavant, Pharmaceutical industry, Wayfinder

FRANKLIN, Tenn., Nov. 7, 2023 /PRNewswire/ -- Kythera Labs, a leading healthcare technology and data analytics company for the Healthcare and Life Sciences industries, announces $20 Million in Series A and debt financing from BIP Ventures and CIBC. The company will use the funds to support the continued growth and scale of Wayfinder, its data-transforming technology platform, and accelerate the development and adoption of new and existing offerings. Kythera also plans to leverage financing to expand partnerships with industry leaders such as Datavant and Databricks.

Key Points: 
  • The company will use the funds to support the continued growth and scale of Wayfinder, its data-transforming technology platform, and accelerate the development and adoption of new and existing offerings.
  • Kythera Labs' data technology platform, Wayfinder, provides access to real-world healthcare data spanning over 8 years, including over 320 million lives with 29.3 billion encounters.
  • Wayfinder corrects, enhances, and adds new dimensions to healthcare data, using a dynamically improving common data model that facilitates data integration.
  • Roivant Sciences adopted Kythera Labs' platform and refined analytics to more efficiently and accurately support its pre-commercialization activities.

FPT Acquires Product Engineering Services Firm Cardinal Peak

Retrieved on: 
Monday, November 6, 2023
Software, Networks, Professional Services, Hardware, Robotics, Consumer Electronics, IOT (Internet of Things), Technology, Artificial Intelligence, Security, Data Analytics, Other Technology, Internet of things, Cardinal Peak, LTS, Optimism, Family, FPT Software, Acquisition, RWE, Multimedia, FPT, FPT Corporation, Health, USD, Culture, Safety, AI, Retail, Management, Intellinet

Vietnam’s leading corporation FPT announces its acquisition of the US-based company Cardinal Peak, a strategic move to strengthen its product engineering delivery capabilities in North America.

Key Points: 
  • Vietnam’s leading corporation FPT announces its acquisition of the US-based company Cardinal Peak, a strategic move to strengthen its product engineering delivery capabilities in North America.
  • With these additional resources, the global IT firm sets its sights on doubling its product engineering services revenue in the Americas in the next two years.
  • FPT and Cardinal Peak expressed their alignment in ways of working and a people-focused mindset, as well as optimism for future opportunities.
  • FPT Corporation CEO Nguyen Van Khoa expects that the synergy between FPT and Cardinal Peak will result in new digital products, contributing to the advancement of Vietnam’s IT industry.

Verana Health Partners with Foundation Fighting Blindness to Integrate Genetic Testing Data into Real-World Evidence Research

Retrieved on: 
Thursday, November 2, 2023
Health Technology, Data Management, Other Health, Technology, Optical, General Health, Professional Services, Philanthropy, Genetics, Clinical Trials, Foundation, Biotechnology, Science, Data Analytics, Research, Health, Genetic testing, IRIS, Biomarker, Ophthalmology, Foundation Fighting Blindness, Data, RWE, Visual impairment, Genomics, Medicine, American Academy, Machine Intelligence Research Institute, Retina, American Academy of Ophthalmology, Partnership, Patient, Pharmaceutical industry, Nursing

Under the partnership, the Foundation will provide Verana with de-identified genomics data from its My Retina Tracker® Registry to support clinical research surrounding patients with inherited retinal degenerative diseases.

Key Points: 
  • Under the partnership, the Foundation will provide Verana with de-identified genomics data from its My Retina Tracker® Registry to support clinical research surrounding patients with inherited retinal degenerative diseases.
  • This groundbreaking partnership leverages the Foundation’s de-identified genomics and patient-reported data on tens of thousands of individuals with inherited retinal degenerative diseases to support commercial real-world evidence (RWE) clinical research initiatives.
  • As part of its mission to drive the research that will provide preventions, treatments and cures for people affected by retinal degenerative diseases, the Foundation Fighting Blindness provides no-cost genetic testing to people with inherited retinal diseases.
  • Through its partnership with the Foundation Fighting Blindness, Verana will be able to incorporate the Foundation’s detailed genomics and patient-reported data, along with IRIS Registry data, into its client-facing clinical research initiatives.

Graticule Strengthens Its Leadership With the Appointment of David Legge as Director of Business Development

Retrieved on: 
Wednesday, November 1, 2023
Science, Software, Other Science, Research, Consulting, Data Management, Professional Services, Technology, Business development, Partnership, Entrepreneurship, RWE, Multimedia, Graticule

Graticule, a Real-world data CRO that conducts life science research and development projects with US and international data partners, announces the onboarding of David Legge as Director of Business Development.

Key Points: 
  • Graticule, a Real-world data CRO that conducts life science research and development projects with US and international data partners, announces the onboarding of David Legge as Director of Business Development.
  • Before this, he honed his skills as a Business Development Representative at Recombinant Data, working alongside Graticule CTO Dan Housman.
  • Notably, Recombinant Data Corp, a bootstrapped company was acquired by Deloitte in 2012, where he continued as a Business Development Manager until 2014.
  • Dan Housman, Co-Founder and CTO of Graticule, quoted, “David's role at Graticule marks the reuniting of our partnership.

NRG Energy and City of Pittsburgh Extend Collaboration with Wind Power

Retrieved on: 
Monday, October 30, 2023
Other Energy, Utilities, Oil, Gas, Coal, Alternative Energy, Energy, Nuclear, Sport, Primary energy, NYSE, Stadium Authority of the City of Pittsburgh, Sports & Exhibition Authority of Pittsburgh and Allegheny County, Pittsburgh Parking Authority, Scioto, WPEC, Wind, RWE, Pittsburgh Water and Sewer Authority, Senior, Carbon footprint, Renewable Energy Certificate (United States), City, Environment, Progress Energy Inc, Pittsburgh Zoo & PPG Aquarium, NRG, NRG Energy, Direct Energy, Renewable energy

NRG Energy Inc. (NYSE:NRG) is pleased to announce the renewed collaboration between its brand Direct Energy and the Western Pennsylvania Energy Consortium (WPEC), led by the City of Pittsburgh and its partner organizations.

Key Points: 
  • NRG Energy Inc. (NYSE:NRG) is pleased to announce the renewed collaboration between its brand Direct Energy and the Western Pennsylvania Energy Consortium (WPEC), led by the City of Pittsburgh and its partner organizations.
  • Beginning in 2016, Direct Energy has worked with WPEC and the City of Pittsburgh—in collaboration with Enel North America—to help move the city toward a more sustainable future.
  • “The city’s continued collaboration with NRG Energy assists us in having cleaner energy without the high cost for our facilities which helps our communities.
  • The consortium boasts more than 20 local members including the City of Pittsburgh, Pittsburgh Zoo, Sports and Exhibition Authority, Pittsburgh Water and Sewer Authority, Parking Authority, Stadium Authority, and numerous surrounding boroughs.

Frost & Sullivan Honors Komodo Health with Technology Innovation Leadership Award for Its Data-Driven Platform to Improve Patient Care

Retrieved on: 
Thursday, November 2, 2023
Komodo, Sentinel, RWD, Frost, Health care, Health, Health information management, Shredding (disassembling genomic data), Algorithm, Entrepreneurship, RWE, Research, Enterprise, Genomics, Disease, EHR, Cause of action, Patient, Diagnosis, Pulse, SAN, Software as a service, Medical device, Pharmaceutical industry, Sales, Aperture

SAN ANTONIO and SAN FRANCISCO, Nov. 2, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the real-world evidence (RWE) IT solutions industry and, based on its findings, recognizes Komodo Health with the 2023 North American Technology Innovation Leadership Award. Komodo is an American software-as-a-service (SaaS) provider that converts vast amounts of data into meaningful insights to increase productivity and deliver exceptional value to its healthcare customers.

Key Points: 
  • Moreover, Komodo's solutions are fully scalable and customizable and can integrate seamlessly with today's technology and business tools.
  • "Essentially, it offers a seamless way for clients to integrate their IT systems with its platform without a rip-and-replace approach.
  • Thus, Komodo prioritizes providing a scalable and efficient platform that delivers customer satisfaction by leveraging technology and providing thought partnerships where necessary," said Ojaswi Rana, Best Practices Research Analyst at Frost & Sullivan.
  • Frost & Sullivan Best Practices Awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development.

Frost & Sullivan Honors Komodo Health with Technology Innovation Leadership Award for Its Data-Driven Platform to Improve Patient Care

Retrieved on: 
Thursday, November 2, 2023
Komodo, Sentinel, RWD, Frost, Health care, Health, Health information management, Shredding (disassembling genomic data), Algorithm, Entrepreneurship, RWE, Research, Enterprise, Genomics, Disease, EHR, Cause of action, Patient, Diagnosis, Pulse, SAN, Software as a service, Medical device, Pharmaceutical industry, Sales, Aperture

SAN ANTONIO and SAN FRANCISCO, Nov. 2, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the real-world evidence (RWE) IT solutions industry and, based on its findings, recognizes Komodo Health with the 2023 North American Technology Innovation Leadership Award. Komodo is an American software-as-a-service (SaaS) provider that converts vast amounts of data into meaningful insights to increase productivity and deliver exceptional value to its healthcare customers.

Key Points: 
  • Moreover, Komodo's solutions are fully scalable and customizable and can integrate seamlessly with today's technology and business tools.
  • "Essentially, it offers a seamless way for clients to integrate their IT systems with its platform without a rip-and-replace approach.
  • Thus, Komodo prioritizes providing a scalable and efficient platform that delivers customer satisfaction by leveraging technology and providing thought partnerships where necessary," said Ojaswi Rana, Best Practices Research Analyst at Frost & Sullivan.
  • Frost & Sullivan Best Practices Awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development.

RoadMap Technologies Expands Privacy Solutions to Support JSON Based De-Identification, FDA Clinical Trials, and Healthcare Claims

Retrieved on: 
Thursday, October 26, 2023
Health care, HIPAA, HITRUST, JSON, De-identification, Data science, RWE, Roadmap, Real, DE, Risk, Forecasting, Medical device

BEVERLY, Mass., Oct. 26, 2023 /PRNewswire/ -- RoadMap Technologies, a leading provider of data science and software solutions for the Life Sciences industry, today announced that RoadMap has expanded its HITRUST certified platform to support JSON-based De-identification, as well as FDA Clinical Trials and Healthcare Claims data sets.

Key Points: 
  • BEVERLY, Mass., Oct. 26, 2023 /PRNewswire/ -- RoadMap Technologies, a leading provider of data science and software solutions for the Life Sciences industry, today announced that RoadMap has expanded its HITRUST certified platform to support JSON-based De-identification, as well as FDA Clinical Trials and Healthcare Claims data sets.
  • RoadMap's De-identification engine allows for healthcare companies to safely and securely turn HIPAA protected patient health information into patient data which can be leveraged for robust analytics.
  • RoadMap is one of the few encryption engines that surpasses the SHA-256 encryption standard by integrating proprietary methodologies to both pre-encrypt and post-encrypt tokens.
  • Clinical Trials data are the most under-utilized resources for new product forecasting and commercialization in the Life Sciences industry.